According to latest Symphony Health Solutions Rx data, Zubsolv tablets (4-week rolling average) show a market share of 6.06% (6.09%). The total number of Zubsolv tablets sold week 41 (40) reached 345,472 (339,408). Zubsolv prescriptions (TRx) recorded a market share (4-week rolling average) of 6.15% (6.19%), totaling 12,620 (12,179) prescriptions during the week. The overall market (buprenorphine/naloxone products) showed a y/y growth rate of 8.5% (7.4%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 7.6% (6.6%) (4-week rolling average).